CGEM
Cullinan Oncology LLC
15.40$
-8.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.1% | -7.2% | +51.6% | -4.1% | -4.8% | -6.8% | -10.2% | -7.0% | -7.4% | -10.1% | -9.7% | |
| – | +0.7% | -7.2% | +52.1% | -12.7% | -30.0% | -23.4% | -13.2% | +24.0% | +13.0% | -6.6% | -5.4% | |
| – | +51.8% | -24.6% | +55.0% | -11.2% | -18.7% | -7.7% | -5.0% | +41.9% | -14.5% | -15.0% | +4.7% | |
| – | +0.1% | -7.3% | +53.0% | -12.7% | -31.0% | -23.8% | -12.6% | +25.3% | +13.6% | -6.9% | -4.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +17.0% | -21.5% | +5.2% | +1.6% | +24.0% | -11.6% | +1.2% | +16.2% | +21.0% | -7.1% | +14.2% | |
| – | +20.0% | -22.1% | +7.1% | +3.1% | +26.6% | -10.8% | +2.6% | +16.7% | +15.2% | -6.9% | +15.6% | |
| – | -58.5% | -7.7% | -8.6% | +3.5% | +3.5% | +3.5% | +3.5% | -14.8% | -34.3% | -7.1% | -8.1% | |
| – | +162.1% | +48.7% | -58.1% | +36.0% | -20.5% | +102.2% | -27.6% | -30.0% | -51.2% | +198.3% | +48.5% | |
| – | -3.2% | -6.2% | +54.2% | -4.3% | -6.0% | -6.5% | -10.8% | -8.3% | -9.4% | -10.4% | -12.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.5% | +28.0% | +6.0% | +0.4% | +0.6% | +0.2% | +0.0% | +0.3% | +0.0% | +3.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.